EU Marketing Authorisation change for Maviret
The authorisation shortens the treatment period from from 12 to eight weeks.
Read More
Tag: pibrentasvir
US approves first all-genotype treatment for pediatric hepatitis C
AbbVie’s Mavyret treats all six genotypes of hepatitis C virus.
Read More
AbbVie’s pan-genotypic hep C therapy cleared in the US
AbbVie’s hepatitis C therapy Mavyret has picked up an approval in the US just days after having been green lighted by regulators in Europe.
Read More
New hepatitis C therapies approved in Europe
Patients with hepatitis C in Europe could soon gain access to two new pan-genotypic treatment options after the European Commission issued approval for AbbVie’s Maviret and Gilead’s Vosevi following an accelerated review.
Read More
UK patients get early access to AbbVie’s hepatitis regimen
AbbVie’s glecaprevir/pibrentasvir (G/P) has become the first treatment for chronic hepatitis C to be included in the UK’s Early Access to Medicines Scheme (EAMS).
Read More
AbbVie reports 99% cure rate for pan-genotypic Hep C therapy
AbbVie has released late-stage clinical data showing high cure rates for its experimental ribavirin-free hepatitis C therapy glecaprevir/pibrentasvir (G/P) across the majority of patients infected with the virus.
Read More
Speedy EU review for AbbVie’s pan-genotypic hep C therapy
European regulators are undertaking a speedy review of AbbVie’s investigational, pan-genotypic regimen of glecaprevir (ABT-493)/pibrentasvir (ABT-530) (G/P) for the treatment of chronic hepatitis C (HCV) in all major genotypes.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
